SPRY ARS PHARMACEUTICALS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 7 analyst firms say about ARS PHARMACEUTICALS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
5 rated views · 7 analyst/firm records · 7 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (2)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (2)
Recent analyst activity · last 90 days
Our tracked history has 5 reports on SPRY from 4 analyst firms in the last 90 days (7 firms in the past year).
Comparing each firm's latest target with its previous one: 1 lowered it and 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Latest observed target change: SVB Leerink lowered its target from $18.00 (set 13 Aug 2026) to $15.00 on 8 Sep 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Josh Schimmer | Buy | 14 Aug 2026 | 30.00 USD |
| Leerink Partners | Roanna Ruiz | — | 8 Sep 2026 | 15.00 USD |
| Northland Capital Markets | Unnamed analyst | Buy | 9 Apr 2026 | 25.00 USD |
| Raymond James | Ryan Deschner | Buy | 17 May 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 17 Aug 2026 | — |
| William Blair | Lachlan Hanbury-Brown | Buy | 13 Oct 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 25 Feb 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 07:06 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.